Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells

Auris Nasus Larynx

Volumn 33, Issue 4, 2006, Pages 441-446

  Xu, Jie Jie ^a   Yao, Kun ^a   Yu, Chen Jie ^a   Chen, Xi ^a   Lu, Mei Ping ^a   Sun, Hua ^a   Li, Bai Zhou ^a   Ding, Chuan Ning ^a   Zhou, Feng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cytotoxicity T lymphocyte; Dendritic cell; Epstein Barr virus; Latent membrane protein 2A; Nasopharyngeal carcinoma

Indexed keywords

B7 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 4; LATENT MEMBRANE PROTEIN 2; MEMBRANE ANTIGEN; T6 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; VIRUS PROTEIN;

ADENOVIRUS; ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; EPSTEIN BARR VIRUS; FEASIBILITY STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MONOCYTE; MORPHOLOGICAL TRAIT; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; TUMOR IMMUNITY; TUMOR MODEL; VIRUS CULTURE; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEASIBILITY STUDIES; FEMALE; MICE; MICE, INBRED BALB C; NASOPHARYNGEAL NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VIRAL MATRIX PROTEINS;

EID: 33749234794     PISSN: 03858146     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anl.2006.05.019     Document Type: Article

References (24)

1. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
2. Redchenko I.V., and Rickinson A.B. Accessing Epstein-Barr virus specific T cell memory with peptide loaded dendritic cells. J Virol 73 (1999) 334-342
3. Zitvogel L., Mayordomo, Tjandrawan T., DeLeo A.B., Clarke M.R., Lotze M.T., et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation and T helper cell 1-associated cytokines. J Exp Med 183 (1996) 87-97
4. Ashley D.M., Faiola B., Nair S., Hale L.P., Bigner D.D., and Gilboa E. Bonemarrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186 (1997) 1177-1182
5. Baumforth K.R., Young L.S., Flavell K.J., Constandinou C., and Murray P.G. The Epstein-Barr virus and its association with human cancers. Mol Pathol 52 (1999) 307-322
6. Khanna R. Immune regulation in Epstein-Barr virus associated diseases. Microbiol Rev 59 (1995) 387-405
7. Bollard C.M., Straathof K.C.M., Huls M.H., Leen A., Lacuesta K., Davis A., et al. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother 27 (2004) 317-327
8. + killer T cells. J Exp Med 193 (2001) 405-411
9. Zhang H.Y., Yao K., Zhu H.C., and Glaser R. Expression of the Epstein-Barr virus genome in a nasopharyngeal carcinoma epithelial tumor cell line. Int J Cancer 46 (1990) 944-949
10. Su Z., Peluso M., Raffegerst S.H., Schendel D.J., and Roskrow M.A. The generation of LMP2A-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgin disease. Eur J Immunol 31 (2001) 947-958
11. Gahn B., Siller-Lopez F., Pirooz A.D., Yvon E., Gottschalk S., Longnecker R., et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer 93 (2001) 706-713
12. Progador A., Snyder D., and Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immumol 156 (1996) 2918-2926
13. Celluzzi C.M., Mayordomo J.I., Storkus W.J., Lotze M.T., and Falo Jr. L.D. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 183 (1996) 283-287
14. Romani N. Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability. J Immumol Meth 196 (1996) 137-151
15. Sallusto F., and Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor-α. J Exp Med 179 (1994) 1109-1118
16. Romain N., Gruner S., Brang D., Kampgen E., Lenz A., Trockenbacher B., et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 180 (1994) 83-93
17. Levitskaya J., Coram M., Levitsky V., Imreh S., Steigerwald-Mullen P.M., Klein G., et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen 1. Nature 375 (1995) 685-688
18. Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. J Clin Pathol: Mol Pathol 53 (2000) 248-254
19. Murray R.J., Kurilla M.G., Brooks J.M., Thomas W.A., Rowe M., Kieff E., et al. Identification of target antigens for the human cytotoxic T-cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 176 (1992) 157-168
20. Lee S.P., Tierney R.J., Rosemary J.T., Thomas W.A., Brooks J.M., and Rickinson A.B. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol 158 (1997) 3325-3334
21. Konishi K., Maruo S., Kato H., and Takada K. Role of Epstein-Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation. J Gen Virol 82 (2001) 1451-1456
22. Song W., Kong H.L., Carpenter H., Torii H., Granstein R., Rafii S., et al. Dentritic cells genetically modified with an adenovirus vector encoding the cDNA for a model tumor antigen induce protective and therapeutic antitumor immunity. J Exp Med 186 (1997) 1247-1256
23. Wan Y., Bramson J., Carter R., Graham F., and Gauldie J. Dentritic cells transduced with an adenovirus vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther 8 (1997) 1355-1363
24. Zhong L., Piperno A.G., Choi Y., and Steinman R.M. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 29 (1999) 964-972